Active Recombinant Full Length Human CDK4 Protein, GST-tagged

• Cat.No.: CDK4-4867HF
• Product Overview: Full-length human CDK4 [1-303(end) amino acids of accession number NP_000066.1] was co-expressed as N-terminal GST-fusion protein (61 kDa) with human GST-CyclinD3 [1-292(end) amino acids of accession number AAA51927.1] using baculovirus expression system. GST-CDK4/CycD3 was purified by using glutathione sepharose chromatography and activated with His-tagged CDK7. Activated GST- CDK4/CycD3 was purified using glutathione sepharose chromatography.

Specification

• Source: Insect (sf21)
• Species: Human
• Tag: GST
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was measured by off-chip mobility shift assay. The enzyme was incubated with fluorecence-labeled substrate and Mg(or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by LabChip™3000.
• Protein length: 1-303(end)
• Purity: 84%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: cyclin-dependent kinase 4
• Official Symbol: CDK4
• Synonyms: CDK4;CMM3;PSK-J3
• Protein Refseq: NP_000066.1
• UniProt ID: P11802

Reviews

02/18/2023

Whether it's troubleshooting experimental issues, providing guidance on experimental design, or answering any inquiries related to the CDK4 protein, the manufacturer is committed to helping researchers overcome challenges and achieve their scientific goals.

02/16/2020

They actively seek feedback and incorporate it into their product development process, continuously improving the quality and performance of the CDK4 protein.

05/29/2018

The manufacturer also values customer satisfaction and strives to maintain a strong relationship with researchers.

Q&As

Are there any potential challenges in targeting CDK4 for cancer therapy?

Resistance to CDK4 inhibitors and the need for patient stratification are some of the challenges in using CDK4 as a therapeutic target.

Can CDK4 be targeted for cancer therapy?

Yes, CDK4 is a target for cancer therapy, and drugs that inhibit CDK4 have been developed for the treatment of specific cancers.

How is CDK4 clinically relevant?

CDK4 is clinically relevant because it plays a crucial role in the development and progression of various cancers.

Which cancers are commonly associated with CDK4 overactivity?

CDK4 overactivity is commonly associated with breast cancer, melanoma, and liposarcoma.

How does CDK4 relate to cell senescence?

CDK4 can promote cell senescence, a state of irreversible growth arrest, which has implications in cancer therapy.